BioCentury | Mar 5, 2020
Emerging Company Profile

AiCure: harnessing AI to boost adherence

...participants used AiCure’s IMA compared with directly observed therapy in a Phase II trial of CHRNA7...
...diagnostics, fraud detection, next-generation labeling, analytics and others Targets CHRNA7 - nicotinic acetylcholine receptor alpha 7 Inhua Muijrers-Chen, Associate Editor AbbVie Inc. Nicotinic acetylcholine receptor alpha 7 (CHRNA7)...
BioCentury | Jan 8, 2019
Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting inflammatory macrophages could help treat Type II diabetes-associated pain. In a mouse model of Type II diabetes, the macrophage-targeting immunotoxin Mac1-saporin decreased disease-induced mechanical allodynia compared with vehicle. Also...
BioCentury | Nov 26, 2018
Distillery Therapeutics

Cancer

...brain cancer; lung cancer; neuroendocrine tumors Cell culture studies identified a nicotonic acetylcholine receptor α7 (CHRNA7...
...tool compound and a previously reported resveratrol-based mitochondrial-targeted compound yielded a compound that bound human CHRNA7...
...animal models of those cancers. Bionomics Ltd. has BNC210, a negative allosteric modulator (NAM) of CHRNA7...
BioCentury | Oct 26, 2018
Company News

Stanford launches cannabinoid company Katexco for inflammatory disorders

...Stanford, the co-founders showed that a receptor for amyloid proteins associated with neurological diseases -- nicotinic acetylcholine receptor alpha 7 (CHRNA7)...
...immune cells and help treat inflammatory disorders. Katexco plans to develop small molecule agonists of CHRNA7...
...Crohn's disease. Stanford University, Stanford, Calif. Katexco Pharmaceuticals Corp., Toronto, Ontario Business: Autoimmune, Endocrine/Metabolic Mary Romeo Stanford University Nicotinic acetylcholine receptor alpha 7 (CHRNA7) Katexco...
BioCentury | Oct 5, 2018
Clinical News

Bionomics discontinues BNC210 for PTSD after Phase II miss

...doses of BNC210. BNC210 is a negative allosteric modulator of nicotinic acetylcholine receptor α 7 (CHRNA7...
...Merck & Co. Inc. (NYSE:MRK) in 2014. BNC375 is a positive allosteric modulator (PAM) of CHRNA7...
...Business: Neurology Molecular target: Nicotinic acetylcholine receptor α 7 (CHRNA7) Description: Negative allosteric modulator of CHRNA7...
BioCentury | May 4, 2018
Financial News

Attenua raises $35M series A

...of lead candidate ATA-101 (formerly TC-5619) to treat chronic cough. The company acquired the neuronal nicotinic acetylcholine receptor alpha 7 (CHRNA7)...
...in a Phase II trial to treat ADHD. Attenua also purchased discontinued candidates TC-6987, a CHRNA7...
...in 2016 (see BioCentury, June 13, 2016) . Attenua Inc., Mountain View, Calif. Jaime De Leon Attenua Inc. Nicotinic acetylcholine receptor alpha 7 (CHRNA7) Nicotinic...
BioCentury | Apr 30, 2018
Financial News

Cough company Attenua raises $35M series A, names CEO

...of lead candidate ATA-101 (formerly TC-5619) to treat chronic cough. The company acquired the neuronal nicotinic acetylcholine receptor alpha 7 (CHRNA7)...
...in a Phase II trial to treat ADHD. Attenua also purchased discontinued candidates TC-6987, a CHRNA7...
...Co. Inc. (NYSE:MRK) acquired in 2016 (see BioCentury Extra, June 9, 2016) . Jaime De Leon Attenua Inc. Nicotinic acetylcholine receptor alpha 7 (CHRNA7) Nicotinic...
BioCentury | Feb 16, 2017
Company News

Bionomics, Merck deal

...Phase I trial evaluating BNC375 for AD. BNC375 is a positive allosteric modulator (PAM) of nicotinic acetylcholine receptor alpha 7 (CHRNA7)...
...Thebarton, Australia Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Neurology Nora Weintraub BNC375 Bionomics Ltd. Merck & Co. Inc. Nicotinic receptor alpha 7...
BioCentury | Dec 13, 2016
Distillery Therapeutics

Inflammation

...INDICATION: Asthma Cell culture and mouse studies suggest CHRNA7 agonists could help treat allergic asthma. In...
...help treat allergic asthma. In a mouse model of airway hyperresponsiveness, intranasal administration of a CHRNA7...
...partial agonist of CHRNA7, in Phase I testing for schizophrenia. TARGET/MARKER/PATHWAY: Nicotinic acetylcholine receptor α7 (CHRNA7...
BioCentury | Oct 31, 2016
Company News

Catalyst Biosciences deal

Catalyst will sell TC-6499 to an undisclosed buyer for $750,000 up front and up to $37 million in milestones, plus undisclosed royalties. Catalyst, which gained the products when it merged with Targacept Inc. , declined to...
Items per page:
1 - 10 of 238